HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gigantic Parfums to sell licenses

This article was originally published in The Rose Sheet

Executive Summary

Led by former Parlux CEO, President and Chairman Ilia Leckach, Fort Lauderdale, Fla.-based Gigantic Parfums has entered into an agreement to sell some of its fragrance licenses with branding and licensing firm GLMAC and Lucien Lallouz, according to a May 25 release. GLMAC will evaluate Gigantic's license portfolio, assess marketable opportunities and identify potential buyers, release states. Lallouz and GLMAC previously facilitated the sale of Perry Ellis, Paris Hilton, Guess, Maria Sharapova and Baby Gund fragrance licenses for Parlux

You may also be interested in...

Global AMR R&D Hub launches Dynamic Data Dashboard

The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.

AzarGen And iBio Push On With Plant-Based Rituximab

AzarGen and iBio have advanced their alliance, with the latter revealing it would now begin manufacturing and characterizing additional supplies of plant-based rituximab, to enable pre-clinical studies comparing it with Roche’s MabThera original.

EMA Panexcell Review Leads Tillomed To Pull Doxorubicin

Emcure’s Tillomed has been forced to withdraw its application for a version of doxorubicin, in light of the EMA taking a closer look at medicines for which study data prepared by Panexcell Clinical Laboratories was used to support marketing authorization applications.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts